| Bioactivity | Procyclidine (Tricyclamol; (±)-Procyclidine), an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy[1][2]. |
| In Vivo | Procyclidine (subcutaneous injection, 0.3-6.0 mg/kg) in combination with physostigmine (PhS) increases protection in a dose-dependent manner in rats and guinea pigs infected with soman and can prevent seizures altogether[1]. Animal Model: |
| Name | Procyclidine |
| CAS | 77-37-2 |
| Formula | C19H29NO |
| Molar Mass | 287.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yun-Bae Kim, et al. Effects of combinational prophylactics composed of physostigmine and procyclidine on soman-induced lethality, seizures and brain injuries. Environ Toxicol Pharmacol. 2002 Jan;11(1):15-21. [2]. Ulrich Ettinger, et al. Effects of procyclidine on eye movements in schizophrenia. Neuropsychopharmacology. 2003 Dec;28(12):2199-208. |